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ABSTRACT
Objective: Determine the prevalence of metabolic abnormalities (MA) and estimate the 10-year 
risk for cardiovascular disease (CVD) among Latin American HIV-infected patients receiving highly 
active anti-retroviral therapy (HAART). Methods: A cohort study to evaluate MA and treatment 
practices to reduce CVD has been conducted in seven Latin American countries. Adult HIV-infected 
patients with at least one month of HAART were enrolled. Baseline data are presented in this analy-
sis. Results: A total of 4,010 patients were enrolled. Mean age (SD) was 41.9 (10) years; median dura-
tion of HAART was 35 (IQR: 10-51) months, 44% received protease inhibitors. The prevalence of 
dyslipidemia and metabolic syndrome was 80.2% and 20.2%, respectively. The overall 10-year risk of 
CVD, as measured by the Framingham risk score (FRF), was 10.4 (24.7). Longer exposure to HAART 
was documented in patients with dyslipidemia, metabolic syndrome and type 2 diabetes mellitus. 
The FRF score increased with duration of HAART. Male patients had more dyslipidemia, high blood 
pressure, smoking habit and higher 10-year CVD than females. Conclusions: Traditional risk factors 
for CVD are prevalent in this setting leading to intermediate 10-year risk of CVD. Modifi cation of 
these risk factors through education and intervention programs are needed to reduce CVD.
Keywords: HAART, HIV, metabolic parameters, cardiovascular risk factors, metabolic syndrome, 
dyslipidemia.
[Braz J Infect Dis 2010;14(2):158-166]©Elsevier Editora Ltda.
INTRODUCTION
Since the introduction of highly active anti-
retroviral therapy (HAART) in 1995, a sig-
nifi cant decrease in mortality was observed in 
HIV-infected patients coupled with a marked 
reduction in the incidence of opportunistic 
infections and certain kind of cancers.1 While 
these achievements are clearly remarkable, 
long-term complications of HAART were soon 
recognized including dyslipidemia, changes 
in body composition, insulin resistance, and 
glucose intolerance, mineral bone disease, and 
lactic acidosis.2,3 These abnormalities may be 
associated with the use of certain anti-retro-
virals such as stavudine, zidovudine and pro-
tease inhibitors, but a net effect of HIV infec-
tion can not be ruled-out. Additionally, current 
evidence suggests that patients on HAART are 
at risk of developing cardiovascular disease 
(CVD), and recent studies reported a higher 
prevalence of traditional risk factors for CVD 
in HIV-infected patients than in non-infected 
controls, such as arterial hypertension, dysli-
pidemia, and diabetes mellitus.3-9 These com-
plications jeopardize the long-term benefi ts of 
HAART, and make the overall management of 
HIV-infected patients more complex and more 
costly as well.
The World Health Organization reported 
in 2007 that 1.6 million people lived with HIV 
in Latin America; 100,000 new cases were di-
agnosed that year; 58,000 cases died, and ap-
proximately 300,000 cases received HAART.10 
Scaling-up HAART programs are being im-
plemented in the region to a degree that many 
countries provide anti-retroviral therapy free 
of charge to a large proportion of patients. As 
more patients receive HAART in the region, it 
is expected that a similar trend in metabolic 
complications and cardiovascular events is 
likely to be observed. However, the prevalence 
of metabolic complications in these patients is 
largely unknown in the region, and the routine 
evaluation of metabolic parameters is variably 
undertaken both at regional and national levels. 
Therefore, the impact of HAART on metabolic 
abnormalities and CVD has not been elucidat-
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ed in Latin America. We report here pre-intervention data 
on metabolic parameters and risk factors for CVD in a large 
cohort of Latin American HIV-infected patients on HAART 
participating in a study designed to evaluate modalities to 
minimize CVD risk in the region. To our knowledge, this 
is the fi rst attempt to characterize these problems in Latin 
America. The results of our study will allow us not only to 
better understand the long-term complications of HAART 
in Latin America, but also to develop local guidelines to treat 
and prevent CVD.
METHODS
Study design
The RAPID II study (Registry and Prospective Analysis 
of Patients Infected with HIV and Dyslipidemia) is a co-
hort web-based study designed to prospectively collect 
data on demographic, metabolic and treatment modali-
ties among HIV-infected patients receiving HAART from 
Latin America.
Setting
Seven Latin American countries, each one contributing with 
varying number of participating centers from Argentina (16 
centers distributed in Buenos Aires, La Plata and Rosario), 
Brazil (15 centers distributed in São Paulo, Rio de Janeiro, 
Campinas, and Porto Alegre), Chile (two centers in the capi-
tal Santiago), Colombia (3 centers located in Bogotá and 
Cali), Ecuador (11 centers distributed in Quito, Cuenca and 
Guayaquil), Peru (fi ve centers in the capital Lima) and Vene-
zuela (nine centers distributed in Caracas, Valencia, Barqui-
simeto and San Cristobal) participated in the study.
Study population
Inclusion criteria: Patients older than 18 years of age, or 
minimum age as determined by local regulations or as legal 
requirements dictate, of both gender, and with confi rmed 
HIV infection receiving a HAART regimen for at least one 
month prior to enrollment were selected. A lipid profi le had 
to be obtained on every patient at enrollment or within one 
month before it. All patients had to be managed as outpa-
tients from November 2006 to September 2007. 
Exclusion criteria: Patients were excluded if they had 
been enrolled in any clinical trial within one month before 
enrollment or if written consent was not granted.
Procedures
A detailed interview was performed at enrollment to obtain 
demographic data; details of HIV infection, including time 
from diagnosis to enrollment and history of prior anti-retro-
viral medications. Cardiovascular risk factors present before 
enrollment including history of arterial blood hypertension, 
diabetes mellitus, metabolic syndrome, dyslipidemia, smok-
ing habits, family history of premature cardio-vascular dis-
ease and presence of main arterial bed affection were also 
ascertained. Information on smoking, exercising and diet, 
as well as on any medication or lipid lowering intervention 
implemented the two months prior to enrollment was also 
obtained. Patients who had a history of dyslipidemia were 
requested to provide information on any prior lipid inter-
vention undertaken, including diet, exercising and the use 
of lipid lowering drugs. A complete physical examination 
was performed, including measurements of blood pressure, 
weight, height, and waist circumference. A blood sample was 
taken and processed in each participating centre to meas-
ure fasting blood glucose, total cholesterol, HDL-cholesterol 
and LDL-cholesterol, triglycerides, creatine phosphokinase, 
and liver enzymes, including AST and ALT, at enrollment 
and every six months for two years. CD4 cell count and viral 
load determination were also performed at enrollment and 
every six months for two years.
Outcomes
The main outcomes of the study were the determination of 
metabolic risk factors at enrollment and at every six month 
of follow-up for a total of two-years, the evaluation of car-
diovascular events on every follow-up visit, and the lipid 
lowering behaviors of the participating investigators at en-
rollment and subsequently for a total of two-years. 
The following risk factors were evaluated including older 
age (age ≥ 45 years for men and ≥ 55 years for women), cur-
rent cigarette smoking, high blood pressure (systolic blood 
pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 
85 mmHg and/or usage of an antihypertensive drug), low 
HDL-cholesterol (man with ≤ 40 mg/dL or woman with ≤ 
50 mg/dL), high LDL-cholesterol (fasting LDL levels ≥ 130 
mg/dL), dyslipidemia (fasting serum triglycerides ≥ 150 
mg/dL and/or fasting total serum cholesterol ≥ 240 mg/dL 
and/or low HDL-cholesterol and/or high LDL-cholesterol), 
blood lipid normalization (fasting serum triglycerides > 150 
mg/dL and fasting total serum cholesterol < 240 mg/dL and 
HDL-cholesterol > 40 mg/dL and LDL-cholesterol < 130 
mg/dL), type 2 diabetes (fasting serum glucose ≥ 126 mg/dL 
in two measurements at least one week apart and/or usage of 
oral anti-diabetic drugs), physical inactivity (lack of exercis-
ing defi ned as physical activity for at least 30 minutes three 
times-a-week), family history of premature cardiovascular 
disease (presence of cardiovascular disease in either a male 
fi rst-degree relative < 55 years old or a female fi rst-degree 
relative < 65 years old), obesity (body mass index > 30 kg/
m2), established coronary heart disease (history of either 
acute myocardial infarction, or angina, or sudden death, or 
myocardial revascularization), cardiovascular event (coro-
nary heart disease or stroke or transient ischemic attack or 
peripheral artery disease or any combination of the above), 
cardiovascular risk (absolute ten-year-risk of cardiac death 
or myocardial infarction using the Framingham risk factor 
algorithm), high risk patients (those with established or pre-
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dicted ten-year-cardiovascular risk ≥ 20%), abnormal waist 
circumference (man waist perimeter ≥ 102 cm or woman 
waist perimeter ≥ 88 cm), metabolic syndrome following 
ATPIII criteria11 (simultaneous presence of at least three out 
of fi ve of the following: triglycerides ≥ 150 mg/dL, abnor-
mal waist circumference, fasting blood glucose ≥ 110 mg/dL, 
high blood pressure, low HDL-cholesterol), abnormal body 
fat distribution (fat loss from the face or extremities, or cen-
tral fat gain or a mixed pattern). 
The lipid lowering therapeutic behavior of the par-
ticipating investigators in each center was evaluated at en-
rollment and every six-month period for two years. The 
behaviors were classifi ed into four groups: group A cor-
responded to direct lipid treatment and HAART switch-
ing, group B corresponded to direct lipid treatment but 
no HAART switching, group C corresponded to no direct 
lipid treatment and no HAART switching, and group D 
corresponded to no direct lipid treatment and HAART 
switching. The investigators were requested to explain why 
they have selected a specifi c behavior.
Sample size determination and statistical analysis
Assuming rates of serum lipid normalization range from 
10% to 20% and two ratios of dyslipidemic and non-dysl-
ipidemic patients (1:1 and 3:1), a sample size of 4000 indi-
viduals was estimated to provide enough power to conduct 
the analysis of blood lipid normalization of dyslipidemia 
following one the four lipid lowering behaviors. Categori-
cal variables were contrasted with the chi-square test with 
continuity correction or with the Fisher´s exact test. Con-
tinuous variables were contrasted with the student´s t-test 
or the Mann-Whitney test. All tests were two sided, a level of 
signifi cance was pre-defi ned at <0.05. 
Ethical considerations
The study was approved by local and national regulatory 
agencies in each participating center. Each patient signed an 
informed consent form.
RESULTS
A total of 4,010 patients were recruited, three countries 
contributed to 70% of the sample: Argentina enrolled 1,015 
patients, Brazil enrolled 1,001 patients and Venezuela en-
rolled 807 patients. The remaining patients were enrolled by 
Colombia (474 patients), Peru (417 patients), Ecuador (252 
patients) and Chile (44 patients).
Demographic and anthropometric data
Mean age (SD) of the whole population was 41.9 (10) years, 
73.9% of the patients were males. The age and gender distri-
bution of patients is shown in Figure 1. Most of the patients 
were young adults concentrated in the age group of 28-47 
years; only 1.5% had more than 68 years of age. Age distri-
bution by country is shown in Figure 2. No difference across 
countries was observed. Mean body mass index was 24.6 kg/
m2, which was uniformly distributed across the participating 
countries.
HIV related characteristics
All patients were well experienced with HAART, with a me-
dian duration on anti-retroviral therapy of 25 months, Ta-
ble 1. The shortest duration of HAART was observed among 
Peruvian patients and the longest among Brazilian patients: 
18 and 40 months, respectively. A protease inhibitor based 
HAART was used in 44% of patients; Chile reported the 
lowest use of protease inhibitors and Venezuela reported the 
highest: 20% vs. 61.5%, respectively. NNRTI based HAART 
predominated, with 56% of patients receiving such a thera-
py. Chile reported the highest use of a NNRTI and Venezuela 
reported the lowest; 81.8% and 38.2%, respectively. The me-
dian CD4 cell count was 417 cells/mm3; ranging from as low 
as 255 cells/mm3 in Peru to as high as 474 cells/mm3 in Brazil. 
The mean viral load determination was 2.4 log10 copies/mL, 
which was uniformly distributed across countries.
18-27
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Figure 1: Age and gender distribution of patients in the 
RAPID II study. Patients are homogeneously distributed 
across the countries.
Figure 2: Age distribution of patients by country in the 
RAPID II study.
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Metabolic proﬁ le and cardiovascular risk evaluation
Serum biochemical data at enrollment are shown in Table 1,
including serum glucose, triglycerides, total cholesterol, 
HDL and LDL cholesterol, and liver enzymes. Mean values 
for these tests were evenly distributed across the participat-
ing countries.
Cardiovascular and metabolic risk factors prior to enroll-
ment are shown in Table 2. History of dyslipidemia (44.5%) 
and smoking habit (46.7%) were highly prevalent in this co-
hort as reported by patients. Family history of cardiovascu-
lar disease was reported in almost one third of the patients. 
History of diabetes mellitus was obtained in 3.6%. The met-
abolic profi le and cardiovascular risk factors at enrollment 
are shown in Table 3. Cardiovascular risk factors were fre-
quent in this cohort as determined by the high prevalence of 
dyslipidemia (80.2%) and high blood pressure (31.5%). Dy-
slipidemia was driven by high hipertrygliceridemia (55.8%) 
and low-HDL cholesterol values (49.5%). The overall preva-
lence of type 2 diabetes mellitus was observed in 3.3%, but 
was as low as 0.8% in Colombia and as high as 6.8% in Chile. 
Smoking habit was reported in 22.8% of patients at enroll-
ment, but was as high as 50% for Chilean patients and as low 
as 10.3% for Ecuadorian patients. The 10-year overall risk 
of developing CVD was intermediate (10.4), as measured by 
the Framingham risk factor score, but was not evenly dis-
tributed. Brazilian and Chilean patients had the highest 10-
year risk, while Colombian and Ecuadorian patients had the 
lowest 10-year risk. The overall proportion of patients in the 
highest risk group was 10.2%. Longer exposure to HAART 
was documented in patients with dyslipidemia (35.1 vs. 31.6 
months, p = 0.0034), type 2 diabetes (48.4 vs. 33.9 months, 
p < 0.001), and metabolic syndrome (39.4 vs. 33.1 months, 
p < 0.001). The exposure to HAART increased also the 10-
year risk of developing CVD: 0.09 increase in the Framing-
ham risk score per month of exposure.
 A clear gender difference in the risk of developing CVD 
was observed, Table 4. Males were older: mean age (SD) 42.2 
(9.9) vs. 40.8 (10.3) years, p < 0.001, and had higher preva-
lence of dyslipidemia and other traditional risk factors for 
CVD such as high blood pressure and smoking. In contrast, 
females had more prevalence of obesity, abnormal waist cir-
cumference, metabolic syndrome, and lack of exercise. The 
10-year risk of developing CVD was higher in males, and 
more males belonged to the high risk category. Both groups 
were similar in HIV disease severity.
DISCUSSION
The results of this study indicate that among this cohort of 
adult HIV-infected patients well experienced with HAART 
from seven Latin American countries, there is a high preva-
lence of dyslipidemia and intermediate 10-year risk of de-
veloping CVD. Gender differences in the metabolic profi le T
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and cardiovascular risk were observed, with male patients at 
higher risk than females. Obesity and metabolic syndrome 
predominated in females. These results are remarkable and 
stress the necessity of incorporating the evaluation, treat-
ment and prevention of modifi able risk factors and meta-
bolic derangements in HIV-infected patients under HAART 
into routine practice in the region. 
The 10-year risk of developing CVD as measured by the 
Framingham risk factor score was intermediate in this co-
hort of patients, but was not evenly distributed, it was low in 
three countries (Ecuador, Colombia and Peru, < 10%) and 
intermediate in the remaining four (Argentina, Brazil, Chile 
and Venezuela, 10-20%). However, the overall estimated risk 
of CVD in this large cohort of patients was higher than that 
reported for HIV-infected patients on HAART from devel-
oped countries with similar age distribution of subjects.12-
16 These studies estimated the 10-year risk of CVD in the 
low risk category (estimated risk < 10%): 7.0% among 403 
Italian patients,12 7.4% in another Italian study with 1,243 
subjects,13 6.2% in 603 Spanish patients,14 6% in 2,386 
American subjects,15 and 8.8% among 219 Norwegian pa-
tients.16 We did not include a control group from the general 
population in our study, but a comparison of our results 
with those published recently from a large cross-sectional 
study conducted in seven Latin American countries among 
11,550 non-HIV infected subjects found similar results for 
the 10-year risk of CVD, with 83% of these patients in the 
low risk category and approximately 10% in the high risk 
category.17 We used the Framingham risk algorithm to pre-
dict CVD in HIV-infected patients, although it was not de-
signed to predict the CVD risk in this population. Its utility 
to estimate the risk has been questioned more recently, as it 
Table 4. Gender comparison of anthropometric, HIV related and cardiovascular risk factors*
Characteristic Male patients Female patients p value
 (n = 2963) (n = 1047) 
Family history of cardiovascular disease 21.84 23.50 0.280
Abnormal waist circumference 9.7 36.7 < 0.001
Obesity 6.6 11.8 < 0.001
Current smoking 25.0 16.7 < 0.001
Lack of exercise 51.7 58.5 < 0.001
High blood pressure 34.3 23.5 < 0.001
Dyslipidemia 81.3 77.3 < 0.001
Metabolic syndrome 19.4 22.7 0.020
Type 2 diabetes 3.7 3.3 0.631
Mean Framingham risk score (SD)  11.4 (24.7) 7.5 (24.6) < 0.001
High risk category for cardiovascular disease 11.1 6.8 < 0.001
Mean CD4 cell count (SD), cells/mm3 464.8 (270.4) 479.8 (286.) 0.1407
Mean viral load (SD), log
10
 copies/mL 2.4 (1.0) 2.3 (1.0) 0.4344
*Values are % unless noted otherwise
may not be fully applicable to this population of patients.18 
The general consensus is that the score performs reasonably 
well in this population; it tends to over predict the risk in 
unexposed individuals and under predict the risk in exposed 
individuals.18 Better equations are clearly needed to more 
accurately predict the risk of CVD in HIV-infected patients. 
Although the Framingham risk factor may not accurately 
predict the risk of CVD in HIV-infected patients on HAART, 
compelling evidence of an association between HAART and 
CVD comes from the largest cohort of HIV-infected pa-
tients recruited for the Data Collection on Adverse Events of 
anti-HIV drugs study (DAD study).19 The fi rst report of that 
study in 2003 showed that for any year of exposure to anti-
retroviral medications there was a 26% increase in the rate 
of acute myocardial infarction.19 A more recent report after 
completing 5 years of follow-up showed 32% increase in the 
risk of CVD, mainly due to protease inhibitors exposure.20 In 
agreement with these fi ndings, we also observed that longer 
exposure to HAART in our cohort correlated with more risk 
for CVD, as measured by the Framingham risk score, as well 
as with higher rates of dyslipidemia, type 2 diabetes mellitus, 
and metabolic syndrome.
The individual role of traditional risk factors on the 
risk of CVD has been evaluated recently, concluding that 
they contribute in the similar direction in HIV positive and 
negative individuals.9 However, the prevalence of certain 
traditional risk factors such as smoking and dyslipidemia is 
higher in HIV-infected individuals compared to the general 
population, the latter as a direct result from HIV infection 
itself or due to the exposure to anti-retrovirals.19,21-23 Of note, 
the overall prevalence of dyslipidemia (80.2%) and arterial 
blood hypertension (31.5%) in our population was higher 
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compared to that reported from large cohort studies in the 
developed world (45.9% and 7.2%, respectively),19,20 and 
from non-HIV infected subjects in Latin America (6-20% 
and 9-29%, respectively.17 Current or past smoking habit 
in our study was comparable to that reported among HIV-
infected patients23 and non-HIV infected patients in Latin 
America.17 On the other hand, the prevalence of type 2 diabe-
tes mellitus (3.3%) was similar to that reported elsewhere,19 
but lower than that reported in non-HIV infected subjects 
in Latin America (4-8%).17 The contribution of metabolic 
syndrome to the risk of CVD in HIV-infected patients on 
HAART has been challenged recently, as its defi nition may 
not have a good sensitivity for this population.24 The pre-
diction of CVD risk with metabolic syndrome is not more 
accurate than the conferred by its components. The overall 
prevalence of metabolic syndrome in our cohort of HIV-in-
fected patients was similar than that reported elsewhere.25-27 
Gender differences in the risk of CVD among HIV-in-
fected patients on HAART have been reported.20,28 We found 
a predominance of dyslipidemia, smoking habit, and high 
blood pressure among males, resulting in higher risk for 
CVD. In contrast, females presented more metabolic syn-
drome and obesity. Interestingly, obesity was more preva-
lent among females than among males in a large cohort of 
non-HIV-infected patients in Latin America.17 Prevalence 
rates of obesity ranged from 16.8% in Buenos Aires to 30.4% 
in Mexico City in that study. Data from our cohort seem 
to correspond with the global obesity epidemic that affects 
both sexes, but particularly female Latin American subjects.
The study has limitations that should be considered 
when interpreting our results. Firstly, we did not include 
controls from the general population. Comparison of cer-
tain traditional risk factors for CVD, such as smoking habit 
and obesity in the general population of Latin America were 
comparable to those found in our study, but the prevalence 
of dyslipidemia and high blood pressure were markedly dif-
ferent, which may explain the increase risk of CVD observed 
in our patients. The purpose of our study was not to com-
pare the CVD risk in HIV-infected patients with that of the 
general population, but to show the current status of the 
metabolic profi le and CVD risk in HIV-infected patients on 
HAART. Secondly, our convenient sample may not be repre-
sentative of the whole population of HIV-infected patients 
on HAART in Latin America, but to our knowledge this 
study represents the fi rst attempt to elucidate the CVD risk 
among these patients in the region, and its results may be 
used for comparison with studies that might be conducted 
in the future. Lastly, some risk factors unique to HIV-infect-
ed patients on HAART such as altered body composition, 
including lypoatrophy and lypodistrophy could not be eval-
uated in this cohort of patients. Some studies have found 
a correlation between body composition and metabolic de-
rangements that we were not able to ascertain in this study. 
In summary, the intermediate 10-year risk of CVD ob-
served in this population resulted from the high prevalence 
of traditional risk factors for CVD, and points out the ne-
cessity of implementing programs to reduce it. Intervention 
strategies should focus on smoking cessation, dietary coun-
seling, increase exercise, and treatment of arterial blood hy-
pertension and dyslipidemia, together with modifi cation of 
HAART regimens when needed. 
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